Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Axsome Therapeutics, Inc.

Market Cap 12.89B 11.26B 10.42B 9.72B 18.26B 1,218B 18.39B 124B 48.17B 599B 48.4B 47.35B 2,081B P/E 2026 *
-126x
P/E 2027 * 43.4x
Enterprise Value 12.78B 11.17B 10.33B 9.64B 18.1B 1,208B 18.23B 123B 47.76B 594B 47.98B 46.94B 2,063B EV / Sales 2026 *
13x
EV / Sales 2027 * 7.82x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 week-1.31%
Current month+8.46%
1 month+11.45%
3 months+59.24%
6 months+66.86%
Current year+69.45%
1 week 207
Extreme 207
225.3
1 month 189.55
Extreme 189.55
225.3
3 years 52.74
Extreme 52.74
225.3
5 years 16.81
Extreme 16.81
225.3
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Change 5-day change 1-year change 3-year change Capi.($)
-0.64%-1.31%+149.77%+175.95% 12.89B
+0.42%-0.40%+19.65%-21.46% 62.05B
-0.84%-9.93%+57.21%+194.41% 54.52B
-5.75%+29.50%+29.50%+29.50% 41.55B
-2.96%+4.99%-53.01%-60.20% 39.06B
+1.59%+0.54%+60.08%-32.06% 29.02B
-7.22%+13.84%+131.18%-50.74% 25.38B
+5.54%+1.65%+54.12%+67.44% 19.62B
-1.05%-1.44%-3.02%+139.59% 16.89B
+1.04%+1.28%+63.17%+110.01% 15.89B
Average -1.05%+2.11%+50.86%+55.24% 33.78B
Weighted average by Cap. -1.34%+0.90%+39.48%+42.99%

Financials

2026 *2027 *
Net sales 985M 861M 796M 743M 1.4B 93.11B 1.41B 9.46B 3.68B 45.78B 3.7B 3.62B 159B 1.6B 1.4B 1.29B 1.21B 2.26B 151B 2.28B 15.34B 5.97B 74.22B 6B 5.87B 258B
Net income -102M -89.42M -82.71M -77.2M -145M -9.67B -146M -983M -382M -4.75B -384M -376M -16.52B 315M 275M 255M 238M 446M 29.79B 450M 3.03B 1.18B 14.64B 1.18B 1.16B 50.87B
Net Debt -111M -96.73M -89.47M -83.51M -157M -10.46B -158M -1.06B -414M -5.14B -416M -407M -17.87B -394M -344M -318M -297M -558M -37.21B -562M -3.78B -1.47B -18.3B -1.48B -1.45B -63.56B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
-
Date Price Change
26-06-22 216.60 -0.64%
26-06-19 218.00 -0.09%
26-06-18 218.20 -0.41%
26-06-17 219.10 +1.01%
26-06-16 216.90 -0.73%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
250.50USD
Average target price
276.47USD
Spread / Average Target
+10.37%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!